semaglutide recombinant synthesis Enzymatic Strategies Behind Manufacturing CN115322250A - Synthesis method of

In an aspect of the present invention, the expressed semapeptide can be cleaved enzymatically in vivo or in vitro (using either pure or partially purified fusion specific protease) by cleavage enzyme which cleaves at the junction between ubiquitin fusion tag and semapeptide to generate the semapeptide

Modifications are also being designed to create biased agonists

la rsine 2-CTC a un degr de substitution de 0,2 0,6 mmol/g

This strategy is disadvantageous because hydrazine, which is a toxic and dangerous reagent, is required for the removal of the Dde protecting group

It summarizes the technical point description of the patent document